Next Article in Journal
Best Practices for Transfusion for Patients with Sickle Cell Disease
Previous Article in Journal
Confirmation of the Validity of Using Birth MCV for the Diagnosis of Alpha Thalassemia Trait
Hematology Reviews (renamed as Hematology Reports here since 2010) is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on as a courtesy and upon agreement with PAGEPress.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:

The Progress of Prothrombin Time Measurement

Centre for Laboratory Medicine, Tampere University Hospital, P.O. Box 2000, FIN-33521 Tampere, Finland
Hematol. Rev. 2009, 1(2), e19; (registering DOI)
Original submission received: 8 June 2009 / Revised: 8 September 2009 / Accepted: 21 October 2009 / Published: 17 December 2009


Warfarin is the most widely used medicine for oral anticoagulant therapy (OAT). It inhibits the synthesis of coagulation factors II, VII, IX, and X in the liver and results in the production of inactive or partially active versions of these factors. Inactive coagulation factors interfere with prothrombin time measurement (Quick and Owren PT) measuring the sum of coagulation activity and inhibition. The narrow therapeutic range here involves a danger of serious complications and the risk of bleeding or thrombosis. The new-generation PT method can measure coagulation activity and inhibition separately. This new technique promotes patient care and anticoagulant medication (warfarin, dicoumarol) based on coagulation activity in vivo. Both therapy and laboratory controls should be unquestionably accurate and based solely on in vivo coagulation activity. Inactive coagulation factors (inhibition) render measurement, calibration, and harmonization. The use of the new-generation PT method based on measurement of coagulation activity in vivo could develop vitamin K antagonist (VKA) therapy for the marked benefit of patients.
Keywords: anticoagulant therapy; INR; oral anticoagulation; vitamin K antagonist; warfarin anticoagulant therapy; INR; oral anticoagulation; vitamin K antagonist; warfarin

Share and Cite

MDPI and ACS Style

Horsti, J. The Progress of Prothrombin Time Measurement. Hematol. Rev. 2009, 1, e19.

AMA Style

Horsti J. The Progress of Prothrombin Time Measurement. Hematology Reviews. 2009; 1(2):e19.

Chicago/Turabian Style

Horsti, Juha. 2009. "The Progress of Prothrombin Time Measurement" Hematology Reviews 1, no. 2: e19.

Article Metrics

Back to TopTop